Johnson & Johnson (JNJ)
| Market Cap | 371.48B |
| Revenue (ttm) | 81.80B |
| Net Income (ttm) | 38.48B |
| Shares Out | 2.41B |
| EPS (ttm) | 15.09 |
| PE Ratio | 10.22 |
| Forward PE | 14.27 |
| Dividend | $4.96 (3.21%) |
| Ex-Dividend Date | May 20, 2024 |
| Volume | 2,654,753 |
| Open | 154.86 |
| Previous Close | 154.28 |
| Day's Range | 153.71 - 154.86 |
| 52-Week Range | 143.13 - 175.97 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 166.21 (+7.65%) |
| Earnings Date | Apr 16, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $166.21, which is an increase of 7.65% from the latest price.
News
Ex-Dividend Reminder: Nuvei, Walgreens And Johnson & Johnson
On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgree...
Johnson & Johnson to acquire Proteologix for $850 million
Johnson & Johnson on Thursday said it would acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment.
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company...
Is Johnson & Johnson Stock A Better Pick Over Merck?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK). Although Merck trades at a higher valuation of 5.5x trailing re...
J&J's $13 billion bid for Shockwave turns to Wall Street for funding
Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dul...
J&J to exit Kenvue, a year after spinoff
Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health bus...
Kenvue Announces Launch of Secondary Offering
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.
SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medica...
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hot...
Pharma giant adds Israel to list of Middle East markets after omission raises questions
Johnson & Johnson has added Israel to its Customer Connect order management website after questions rose over why it was excluded while "Palestine" was not.
Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US
Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S.
Johnson & Johnson Proposes Nearly $6.5B Package to Settle Talc Ovarian Cancer Suits
Johnson & Johnson (JNJ) shares rose in early trading Wednesday after the company announced a plan that would resolve nearly all pending litigation over claims that its talc powder caused ovarian cance...
Johnson & Johnson proposes $6.475 billion settlement in talc lawsuits
Johnson & Johnson (JNJ.N) announced on Wednesday a significant move towards resolving ongoing litigation over its baby powder and other talc products, with a proposed settlement amounting to $6.475 bi...
Beasley Allen Law Firm: Attorneys for Women Harmed by Johnson & Johnson's Talcum Powder Resist Company's Attempt to Stuff Ballot Box in Unprecedented Third Attempted Bankruptcy
MONTGOMERY, Ala.--(BUSINESS WIRE)--A coalition of attorneys representing tens of thousands of women harmed by Johnson & Johnson's talc-based powder products is challenging J&J's attempt to weaponize u...
Johnson & Johnson proposes $6.5bn settlement of talc cancer lawsuits
Deal would resolve tens of thousands of lawsuits alleging company's baby powder causes ovarian cancer
Johnson & Johnson - will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
CNBC's Becky Quick reports on the latest news.
Johnson & Johnson unveils latest plan to settle ovarian cancer talc claims
Johnson & Johnson JNJ, -1.52% unveiled its latest plan to settle ovarian cancer talc claims with the news of a consensual “prepackaged” reorganization of its LTL Management LLC unit, which manages the...
J&J advances $6.475 billion settlement of talc cancer lawsuits
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian ...
Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC ("LLT"), for th...
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S ...
PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit
MILFORD, Conn.--(BUSINESS WIRE)-- #SOC2--PBIRx, a pharmacy benefits consulting and auditing firm, sees growth from concerns over alleged fiduciary breach lawsuit against Johnson & Johnson.
Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton ...
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relati...